



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Medicure, Inc.	Examiner:	Dwayne C. Jones
Serial No.:	10/639,948	Group Art Unit:	1614
Filed:	August 12, 2003	Docket No.:	12695.6USD6
Title:	TREATMENT OF CARDIOVASCULAR AND RELATED PATHOLOGIES		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form PTO-1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits, but before the mailing date of a final action under 37 C.F.R. § 1.113. In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

10/07/2004 JBALINAN 00000135 10639948


01 FC:2253 490.00 DA
02 FC:1806 180.00 DA

10/07/2004 JBALINAN 00000024 132725 10639948
Sale Ref: 00000135 DAH: 132725 10639948
01 FC:2253 490.00 DA
02 FC:1806 180.00 DA


Please charge Deposit Account No. 13-2725 in the amount of \$180.00 for consideration of the items listed on the enclosed Form PTO-1449. A duplicate copy of the Transmittal Sheet is enclosed for this purpose.

Respectfully submitted,

Date: October 6, 2004


Ronald A. Daignault
Reg. No. 25,968

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
202-625-8380



FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

12695.6USD6


Application Number:

10/639,948

Applicant: Medisure, Inc.

Filing Date: August 12, 2003

Group Art Unit: 1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Kuo & Wang, "Pyridoxal Phosphate-Responsive Epilepsy with Resistance to Pyridoxine," <i>Pediatric Neuro.</i> , 26(2):146-147 (2002).
		Onorato, <i>et al.</i> , "Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions," <i>J. Biol. Chem.</i> , 275(28):21177-21184, July 14, 2000.
		Schaumburg, <i>et al.</i> , "Sensory Neuropathy from Pyridoxine Abuse," <i>N. Eng. J. Med.</i> , 309(8):445-448, August 25, 1983.
		Yamashima, <i>et al.</i> , "Neuroprotective Effects of Pyridoxal Phosphate and Pyridoxal Against Ischemia in Monkeys," <i>Nutritional Neuroscience</i> , 4:389-397 (2001).

23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.